help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sabbatini, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sabbatini, P.
The Oncologist, Vol. 5, Suppl 2, 19-23, June 2000
© 2000 AlphaMed Press


SUPPLEMENT

The Relationship between Anemia and Quality of Life in Cancer Patients

Paul Sabbatini

Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Correspondence: Paul Sabbatini, M.D., Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA. Telephone: 212-639-6423; Fax: 212-639-8865; e-mail: sabbatip{at}mskcc.org

Anemia is a common occurrence in patients with cancer, and especially in those who undergo chemotherapy. Traditionally, significantly decreased hemoglobin levels have been considered to be <= 8 g/dl and have been associated with physiologic manifestations. More recent data have shown that milder anemia (hemoglobin levels 10-12 g/dl) has functional consequences as well. This article reviews several communitybased studies that have analyzed changes in hemoglobin concentrations, transfusion requirements, and QOL parameters in anemic patients with cancer before and after treatment with epoetin alfa. The results of these studies have been consistent and show an increase in hemoglobin and a reduction in transfusion requirements when compared with baseline. Furthermore, a relationship between increasing hemoglobin levels and an improvement in QOL is suggested that is independent of tumor response. Additional studies are evaluating the optimal hemoglobin levels for the greatest incremental improvement in QOL.

Key Words. Functional anemia • Epidemiology • Epoetin alfa • Quality of life • FACT-An




This article has been cited by other articles:


Home page
Am J Trop Med HygHome page
K. Tolentino and J. F. Friedman
An Update on Anemia in Less Developed Countries
Am J Trop Med Hyg, July 1, 2007; 77(1): 44 - 51.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. S. Duh, P. Lefebvre, J. Fastenau, C. T. Piech, and R. J. Waltzman
Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve
Oncologist, June 1, 2005; 10(6): 438 - 448.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2000 by AlphaMed Press.